Exclusive Group Transitions Leadership Team for Next Stage of Growth
Exclusive Group, the global value-added services and technologies (VAST) group, today announced Andy Travers as its new SVP Worldwide Sales and Marketing. The ex-Fortinet and RSA executive will be responsible for leading the next phase of Exclusive’s growth strategy to build the world’s biggest specialist VAD in cybersecurity and cloud transformation with targeted revenues of $10bn over the next 5 years.
The appointment coincides with the news that Exclusive Group’s current COO, Barrie Desmond, has decided to step down at the end of 2018 to pursue other interests. Affectionately dubbed ‘Disruptive Desmond’, he has played a key role in developing Exclusive’s go-to-market proposition, market positioning and sales growth over the last 7 years.
Andy Travers is a 25-year veteran of IT channel sales excellence, achieving success at reseller, VAD and global vendor organisations. As SVP of Worldwide Sales and Marketing, Travers will be responsible for steering Exclusive to unprecedented revenues, heading up strategic alliances with major vendors, developing key relationships with GSIs and taking executive control of global services. His previous roles include SVP and VP Sales positions on both sides of the Atlantic for Fortinet, as well as VP EMEA stints at F5 Networks and, most recently, RSA Security.
Commenting on the changes Olivier Breittmayer, Exclusive Group’s CEO said, “Following our recent investment from Permira funds we set ourselves high expectations for executing against our new growth strategy. Andy has the skills and experience necessary to contribute to us achieving our goals and understands our unique culture and values having been in the orbit of Exclusive working with our vendors and channel partners for many years. We are delighted to have him onboard.
“Barrie’s decision to stand down at the end of the year is totally respected by myself and the board. We’ve worked well together these past 7 years, architecting and driving the growth of this business and telling the story only we can tell. It’s been a great journey together and we wish him all the best for the future.”
Commenting on his appointment Andy Travers said, “Exclusive has earned a worldwide reputation for doing what no other VAD has been able to do – delivering genuine value-add at scale. I’m joining at a pivotal time for the business as we commit to exploiting the global opportunities around cybersecurity and cloud transformation to reach another step-change in growth. The investors and management team have developed a winning strategy and now it’s all about the execution. I’m delighted to be joining and really looking forward to helping achieve the next phase of growth.”
Desmond and Travers will work closely together over the next few months to ensure a smooth transition.
Commenting on his decision to leave Exclusive at the end of the year, COO Barrie Desmond said, “My work here is done. We’ve had an incredible journey and built a VAD that continues to disrupt, grow sales at an extraordinary rate and expand its footprint at an astonishing tempo. Along the way we’ve reinvented Distribution and redefined value. But now it’s time for the next generation of disruptors to take on the challenge of growing the world’s largest specialist VAD.”
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181004005109/en/
Contact information
Cohesive
Jon Bawden
+44 (0) 1291 626200
exclusivegroup@wearecohesive.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Enginzyme and AGC Create Scalable Process for Key mRNA Ingredient12.1.2026 07:00:00 EET | Press release
At the mRNA Health conference in Berlin, enginzyme and AGC Inc. presented a scalable process to produce a key mRNA vaccine and therapy ingredient, N1-methylpseudouridine-5'-triphosphate (m¹ΨTP). The rapid growth of mRNA-based vaccines and therapeutics has driven significant demand for modified nucleotides like m¹ΨTP, which enhances mRNA stability and expression, while reducing immunogenicity. Enginzyme is a deep-tech company delivering optimized biomanufacturing solutions through cell-free enzyme engineering technology. AGC Inc. is a leading global player in fields spanning from architectural glass to chemicals and life science. AGC Inc. provides services in a wide range of life science fields, from synthetic pharmaceuticals and agrochemicals, to biopharmaceuticals and leading-edge cell and gene therapies, as well as messenger RNAs. The presentation in November detailed the latest collaboration between the companies, with a focus on the biomanufacturing of nucleotides for mRNA therapy,
Ant International Partners with Google’s Universal Commerce Protocol to Expand AI Capabilities12.1.2026 03:15:00 EET | Press release
Ant International, a leading global payment, digitisation, and financial technology provider, is collaborating on the launch of Google’s Universal Commerce Protocol (UCP), a new open standard for agentic commerce that works across the entire shopping journey — from discovery and buying to post-purchase support. UCP establishes a common language for agents and systems to operate together across consumer surfaces, businesses, and payment providers to enable commerce. So instead of requiring unique connections for every individual agent, UCP enables all agents to interact easily. UCP is built to work across verticals and is compatible with existing industry protocols like Agent2Agent (A2A), Agent Payments Protocol (AP2), and Model Context Protocol (MCP). “For agentic commerce to scale, it’s critical for the industry to align on a common set of standards. We are proud to have Ant International endorse the Universal Commerce Protocol as the foundation for that future,” said Ashish Gupta, VP
Torq Secures $140M Series D at $1.2B Valuation to Lead the AI SOC and Agentic AI Era11.1.2026 18:59:00 EET | Press release
Torq, the established Agentic AI security operations pioneer, today announced it has closed a massive $140 million Series D funding round, propelling its valuation to $1.2 billion and total funding to $332M. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112510774/en/ Led by Merlin Ventures—a leading cybersecurity fund renowned for its deep access to the U.S. commercial and Public Sector markets—with participation from all existing investors, including Evolution Equity Partners, Notable Capital, Bessemer Venture Partners, Insight Ventures Partners, and Greenfield Partners, this capital injection is a definitive investment in the future of security. Torq is driving the industry’s critical shift: the complete transformation of the Security Operations Center (SOC) through battle-tested AI Agents at enterprise scale. The new funds will accelerate the adoption of the Torq AI SOC Platform, the only end-to-end solution built on
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 14:00:00 EET | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreement were not disclosed. “This new agreement builds upon our recent co-development collaboration with Acepodia, which has focused on the evaluation and selection
Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 12:08:00 EET | Press release
Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
